Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2015. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes.
Key transaction details include:
- Transaction Type: Increase in interests in American Depositary Shares (ADSs).
- Transaction Price: $43.14 per ADS.
- Transaction Driver: Re-investment of the dividend paid to shareholders on July 9, 2015.
Material Changes
The filing reports specific increases in ADS holdings for the following individuals:
- Dr M M Slaoui: 1,766.533 ADSs
- Mr W C Louv: 196.531 ADSs
- Mr N Hirons: 221.780 ADSs
- Mr D E Troy: 1,012.516 ADSs
- Dr K Slaoui (Connected Person to Dr M M Slaoui): 77.852 ADSs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share transactions only.
Investor Verification Checklist
- Verify the dividend reinvestment plan terms effective as of July 9, 2015.
- Confirm the market price of GSK ADSs on July 24, 2015, to validate the $43.14 transaction price.
- Review the total shareholding positions of the listed Directors and PDMRs post-transaction.